ArticleJournal of biomedical materials research. Part A2016
Layer-by-layer inorganic/polymeric nanoparticles for kinetically controlled multigene delivery.
Article in Journal of biomedical materials research. Part A, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Layer by Layer Engineered Lipid-Based Nanocarriers for Therapeutic Delivery and Next-Generation Design.Pharmaceutics · 2026Review
- High-Throughput Microfluidic-Mediated Assembly of Layer-by-Layer Nanoparticles.Advanced functional materials · 2025Article
- Layer-by-Layer Nanoparticle Assembly for Biomedicine: Mechanisms, Technologies, and Advancement via Acoustofluidics.ACS applied nano materials · 2024Review
- Modulating the Nature of Ionizable Lipids and Number of Layers in Hyaluronan-Decorated Lipid Nanoparticles for In Vitro Delivery of RNAi.Pharmaceutics · 2024Article
- Gene-Activated Materials in Regenerative Dentistry: Narrative Review of Technology and Study Results.International journal of molecular sciences · 2023Review
- Layer-by-Layer assembled nano-drug delivery systems for cancer treatment.Drug delivery · 2021Article
- Hybrid Nanosystems for Biomedical Applications.ACS nano · 2021Review
- Polymer-Coated Extracellular Vesicles for Selective Codelivery of Chemotherapeutics and siRNA to Cancer Cells.ACS applied bio materials · 2021Article
- Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities.Expert opinion on drug delivery · 2020Review
- Serum-Independent Nonviral Gene Delivery to Innate and Adaptive Immune Cells Using Immunoplexes.ACS applied bio materials · 2020Article
- Non-viral transfection vectors: are hybrid materials the way forward?MedChemComm · 2019Review
- Entanglement-Based Thermoplastic Shape Memory Polymeric Particles with Photothermal Actuation for Biomedical Applications.ACS applied materials & interfaces · 2018Article
- Diacetylenic lipids in the design of stable lipopolymers able to complex and protect plasmid DNA.PloS one · 2017Article
- Engineering nanolayered particles for modular drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nonviral gene delivery methods represent a potential safe and effective approach for treating myriad diseases. For many gene therapy applications, delivering multiple exogenous genes and controlling the time profile that these genes are expressed would be advantageous. Polymeric nonviral gene carriers are versatile and can be readily tailored for particular therapeutic applications, have the ability to carry multiple large genes within each particle, and can be more easily manufactured than viruses used for gene delivery. A layer-by-layer (LbL) theranostic-enabling nanoparticle was developed to incorporate two plasmid types which have differing expression time profiles. Temporally controlling the expression of exogenous DNA enables superior control over the microenvironment and could lead to better control over differentiation pathways and cell fate. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 707-713, 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.